<?xml version='1.0' encoding='utf-8'?>
<document id="23467454"><sentence text="Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance." /><sentence text="Cytochrome P450 2B6 (CYP2B6) belongs to the minor drug metabolizing P450s in human liver" /><sentence text=" Expression is highly variable both between individuals and within individuals, owing to non-genetic factors, genetic polymorphisms, inducibility, and irreversible inhibition by many compounds" /><sentence text=" Drugs metabolized mainly by CYP2B6 include artemisinin, bupropion, cyclophosphamide, efavirenz, ketamine, and methadone"><entity charOffset="44-55" id="DDI-PubMed.23467454.s4.e0" text="artemisinin" /><entity charOffset="57-66" id="DDI-PubMed.23467454.s4.e1" text="bupropion" /><entity charOffset="68-84" id="DDI-PubMed.23467454.s4.e2" text="cyclophosphamide" /><entity charOffset="86-95" id="DDI-PubMed.23467454.s4.e3" text="efavirenz" /><entity charOffset="97-105" id="DDI-PubMed.23467454.s4.e4" text="ketamine" /><entity charOffset="111-120" id="DDI-PubMed.23467454.s4.e5" text="methadone" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e0" e2="DDI-PubMed.23467454.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e0" e2="DDI-PubMed.23467454.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e0" e2="DDI-PubMed.23467454.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e0" e2="DDI-PubMed.23467454.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e0" e2="DDI-PubMed.23467454.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e0" e2="DDI-PubMed.23467454.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e1" e2="DDI-PubMed.23467454.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e1" e2="DDI-PubMed.23467454.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e1" e2="DDI-PubMed.23467454.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e1" e2="DDI-PubMed.23467454.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e1" e2="DDI-PubMed.23467454.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e2" e2="DDI-PubMed.23467454.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e2" e2="DDI-PubMed.23467454.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e2" e2="DDI-PubMed.23467454.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e2" e2="DDI-PubMed.23467454.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e3" e2="DDI-PubMed.23467454.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e3" e2="DDI-PubMed.23467454.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e3" e2="DDI-PubMed.23467454.s4.e5" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e4" e2="DDI-PubMed.23467454.s4.e4" /><pair ddi="false" e1="DDI-PubMed.23467454.s4.e4" e2="DDI-PubMed.23467454.s4.e5" /></sentence><sentence text=" CYP2B6 is one of the most polymorphic CYP genes in humans and variants have been shown to affect transcriptional regulation, splicing, mRNA and protein expression, and catalytic activity" /><sentence text=" Some variants appear to affect several functional levels simultaneously, thus, combined in haplotypes, leading to complex interactions between substrate-dependent and -independent mechanisms" /><sentence text=" The most common functionally deficient allele is CYP2B6*6 [Q172H, K262R], which occurs at frequencies of 15 to over 60% in different populations" /><sentence text=" The allele leads to lower expression in liver due to erroneous splicing" /><sentence text=" Recent investigations suggest that the amino acid changes contribute complex substrate-dependent effects at the activity level, although data from recombinant systems used by different researchers are not well in agreement with each other"><entity charOffset="40-50" id="DDI-PubMed.23467454.s9.e0" text="amino acid" /></sentence><sentence text=" Another important variant, CYP2B6*18 [I328T], occurs predominantly in Africans (4-12%) and does not express functional protein" /><sentence text=" A large number of uncharacterized variants are currently emerging from different ethnicities in the course of the 1000 Genomes Project" /><sentence text=" The CYP2B6 polymorphism is clinically relevant for HIV-infected patients treated with the reverse transcriptase inhibitor efavirenz, but it is increasingly being recognized for other drug substrates"><entity charOffset="123-132" id="DDI-PubMed.23467454.s12.e0" text="efavirenz" /></sentence><sentence text=" This review summarizes recent advances on the functional and clinical significance of CYP2B6 and its genetic polymorphism, with particular emphasis on the comparison of kinetic data obtained with different substrates for variants expressed in different recombinant expression systems" /><sentence text="" /></document>